Related Experiment Video
Updated: Aug 12, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva)
J Lübbe1, I Masouyé, P Y Dietrich
1Service de dermatologie et vénéréologie, Hôpital cantonal universitaire, Geneva, Switzerland. jann.lubbe@hcuge.ch
Abstract:
Erlotinib is a small molecule tyrosine kinase inhibitor that is used as an anticancer agent. Most patients develop a pustular facial dermatitis within the first week of treatment. Pyogenic granulomas of the nail folds are another typical adverse event occurring in about 10-15% of cases. We report on a patient who developed a generalized dermatitis characterized by neutrophilic spongiosis. Neutrophilic inflammation has been observed in several drugs that interfere with EGFR signaling, suggesting a class effect. The present case may be yet another manifestation of this particular reaction pattern.
Insights
Erlotinib, an anticancer drug, commonly causes facial dermatitis and nail fold pyogenic granulomas. A recent case revealed a generalized dermatitis with neutrophilic spongiosis, suggesting a potential class effect of EGFR inhibitors.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Erlotinib is a targeted therapy used in cancer treatment.
- Common side effects include facial dermatitis and pyogenic granulomas.
- These adverse events typically manifest early in treatment.
Observation:
- A patient treated with erlotinib developed a generalized dermatitis.
- The dermatitis was histopathologically characterized by neutrophilic spongiosis.
- This presentation differs from the typical facial rash.
Findings:
- Neutrophilic inflammation is a recognized reaction to drugs inhibiting Epidermal Growth Factor Receptor (EGFR) signaling.
- The observed neutrophilic spongiosis in this case suggests a broader pattern of skin toxicity.
- This reaction may be a class effect associated with EGFR inhibitors.
Implications:
- The findings expand the understanding of erlotinib-induced dermatologic adverse events.
- Recognizing neutrophilic spongiosis as a potential reaction is crucial for diagnosis and management.
- This highlights the need for vigilance regarding diverse skin reactions to EGFR inhibitors in oncology practice.
More Related Videos
06:15Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
04:11A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)
Published on: June 9, 2026